Institute of Hematology & Blood Diseases Hospital is conducting a phase 2 trial to evaluate the safety and efficacy of giving a CM313 injection (which is an anti-Human CD38 Monoclonal Antibody) to treat ITP in adult patients (over 18 years) who are not responsive to steroids, or are steroid-dependent, and may have fail to respond to at least one second-line therapy, including rituximab and/ or TPO agonist. Eligibility is restricted to those who are either in the persistent or chronic phase of ITP (having ITP for more than 3 months) with a platelet count less than 30,000 µL.
China
Recruiting